News Novo Nordisk microRNA drug fluffs its lines in heart failure A microRNA-targeting drug acquired by Novo Nordisk when it bought Cardior in a $1bn-plus deal has generated disappointing results in heart failure.
R&D Partner Content Novo Nordisk seeks to target heart disease with Cardior acqu... Cardior CSO will speak at the Oligonucleotide Therapeutics and Delivery conference following announcement of a buyout by Novo Nordisk to enhance their
News Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure
R&D JP Morgan 2023 – Claudia Ulbrich Last month, pharmaphorum sat down with Claudia Ulbrich, CEO of Germany-based Cardior.
News Novo says Wegovy shot works in childhood obesity Novo has published the results of a trial of its Wegovy injection in children aged six to 12 with obesity, showing the drug reduced their BMI.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.